Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease p…
Sponsor: Replimune, Inc.
NCT ID: NCT06264180
Sites in Utah: - Intermountain Health — Murray, Utah
- Huntsman Cancer Institute — Salt Lake City, Utah
- St. George Regional Hospital — St. George, Utah
Phase 3 Recruiting Industry
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a …
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06585410
Sites in Utah: - University of Utah Hospital — Salt Lake City, Utah
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in Utah: - Retina Associates of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents,…
Sponsor: Immunocore Ltd
NCT ID: NCT05549297
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …
Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Sites in Utah: - Huntsman Cancer Institute, University of Utah 2000 Circle of Hope — Salt Lake City, UT, Utah
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Industry
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifi…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT03645928
Sites in Utah: - Huntsman Cancer Hospital — Salt Lake City, Utah
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Utah: - University of Utah Hospitals & Clinics — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytological…
Sponsor: BioNTech SE
NCT ID: NCT07070232
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Utah: - Clinical Trial Site — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Utah: - University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…
Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Mo…
Sponsor: Strand Therapeutics Inc.
NCT ID: NCT06249048
Sites in Utah: - Huntsman Cancer Institute - University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the ef…
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT03646617
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combin…
Sponsor: University of Utah
NCT ID: NCT06194929
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy. Participants will receive 2 cycles of treatment prior to t…
Sponsor: University of Utah
NCT ID: NCT06365619
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized t…
Sponsor: University of Utah
NCT ID: NCT04844528
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent adva…
Sponsor: Nested Therapeutics, Inc
NCT ID: NCT06326411
Sites in Utah: - START Moutain Region — West Valley City, Utah